WALTHAM, Mass.--(BUSINESS WIRE)--
NeuroMetrix, Inc. (the “Company”) (NURO), a medical device company focused on the treatment and management of the neurological complications of diabetes, today said it plans to issue its 2013 full year and fourth quarter financial results before the opening of the market on February 13, 2014. The Company will host a conference call at 8:00 a.m., Eastern Time on February 13, 2014 to discuss its financial results as well as business developments affecting the Company.
The conference call may be accessed in the United States by dialing 866-515-2913 and using the confirmation code 93917919. Internationally, the conference call may be accessed by dialing 617-399-5127 and using the same confirmation code. The earnings press release and accompanying condensed financial statements will be accessible from the Company's website at www.neurometrix.com under the "Investors" tab.
A replay of the conference call will be available starting two hours after the call by dialing 888-286-8010, domestically and 617-801-6888, internationally. The confirmation code to access the replay is 91113861. The replay will be available for two weeks after the conference call.
NeuroMetrix is a medical device company that develops and markets home use and point-of-care devices for the treatment and management of chronic pain, peripheral neuropathies, and associated neurological disorders. The Company is presently focused on diabetic neuropathies, which affect over 50% of people with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers that may require amputation and cause disabling chronic pain. The annual cost of diabetic neuropathies has been estimated at $14 billion in the United States. The company markets the SENSUS™ Pain Management System for treating chronic pain, focusing on physicians managing patients with painful diabetic neuropathy. The company also markets the DPNCheck® device, which is a rapid, accurate, and quantitative point-of-care test for diabetic neuropathy. This product is used to detect diabetic neuropathy at an early stage and to guide treatment. For more information, please visit http://www.neurometrix.com.
- Health Care Industry
- Company Earnings
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer